Forest Laboratories (FRX) 95.11 $FRX
Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc.
Business Wire - Thu May 22, 2:39PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders.
Research and Markets: Global Neuropathic Pain Report 2014: Grnenthal's Cebranopadol - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 11:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q53s8z/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Global Neuropathic Pain Report 2014: Grunenthal's Cebranopadol - Forecast and Market Analysis to 2022
M2 - Thu May 22, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2vl4/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Gr?nenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Gr?nenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain. Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cebranopadol for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Painful Diabetic Neuropathy - Postherpetic Neuralgia - Trigeminal Neuralgia - Etiology - Pathophysiology 4 Disease Management - Diagnosis - Treatment Overview and Guidelines 5 Competitive Assessment 6 Unmet Need and Opportunity - Physician Knowledge or Awareness - Diagnostic Challenges - Low Treatment Rate and Underdosing of Medications - Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments - Elderly Patient Population - Drug Tolerability - Rational or Personalized Therapies 7 Pipeline Assessment - Promising Drugs in Clinical Development 8 Cebranopadol - Overview - Efficacy - Safety - Dosing and Formulation - Potential Clinical and Commercial Positioning - Pricing and Reimbursement - SWOT Analysis - Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/8s...branopadol
Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition" of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition" of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Conference Schedules, Acquisition Updates, Global Footprints, and Technical Updates - Analyst Notes on Forest, CR Bard, Mallinckrodt, Covidien and WellPoint
PR Newswire - Wed May 21, 8:01AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), CR Bard Inc. (NYSE: BCR), Mallinckrodt plc (NYSE: MNK), Covidien plc (NYSE: COV) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2742-100free.
Adamas Pharmaceuticals awarded USD25m milestone payment for FDA acceptance of MDX-8704 NDA for planned moderate-to-severe dementia of the Alzheimer's type in the US
M2 - Wed May 21, 5:49AM CDT
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of a USD25m milestone payment from Forest Laboratories Holdings related to the development of MDX-8704.
Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
PR Newswire - Tue May 20, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings Limited related to the development of MDX-8704. MDX-8704, a fixed-dosed combination (FDC) of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States.
Will This Price Target Increase Help Forest Laboratory (FRX) Stock Today?
at The Street - Mon May 19, 8:18AM CDT
UBS raises its price target for Forest Laboratory (FRX) to $94 from $72, reiterating its 'neutral' rating, citing a recent takeover offer.
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Forest Laboratories, Inc. to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference
Business Wire - Fri May 16, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it will present data on aclidinium, aclidinium/formoterol combination, and roflumilast at the American Thoracic Society (ATS) 2014 International Conference scheduled for May 16-21, 2014, in San Diego. Ten posters and two poster discussion sessions will be presented for aclidinium and aclidinium/formoterol. Roflumilast data will be highlighted in four posters and one mini symposia presentation.
Forest Laboratories, Inc. to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting
Business Wire - Fri May 16, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that data on an investigational fixed-dose combination (FDC) of nebivolol and valsartan will be presented at the American Society of Hypertension (ASH) Annual Scientific Meeting scheduled May 16-20, 2014 in New York. Forest recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the nebivolol/valsartan FDC for the treatment of hypertension.
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc. -- FURX
GlobeNewswire - Wed May 14, 6:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company" (Nasdaq:FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders.
Synergy Pharma Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 10:00AM CDT
Synergy Pharma (SGYP) reported first quarter 2014 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
Business Wire - Tue May 13, 12:39PM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (NasdaqGS: FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
Business Wire - Tue May 13, 12:34PM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company" (NasdaqGS: FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court.
Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest
PR Newswire - Tue May 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Novartis AG (NYSE: NVS), Cigna Corp. (NYSE: CI) and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2384-100free.
RiverVest Venture Partners' Portfolio Company Lumena is Sold to Shire for $260 million; Represents Sixth Exit from RiverVest Venture Fund II
Business Wire - Mon May 12, 9:39AM CDT
RiverVest Venture Partners today announced portfolio company Lumena Pharmaceuticals has been sold to Dublin-based Shire Plc., in a transaction with an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.
Milestone Payments for Adamas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 22, 4:10PM CDT
Adamas (ADMS) received a milestone payment of $25 million from Forest Labs (FRX) related to MDX-8704.
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection with the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc.
Business Wire - Thu May 22, 2:39PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(NasdaqGS: FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders. Research and Markets: Global Neuropathic Pain Report 2014: Grnenthal's Cebranopadol - Forecast and Market Analysis to 2022
Business Wire - Thu May 22, 11:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q53s8z/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.
Global Neuropathic Pain Report 2014: Grunenthal's Cebranopadol - Forecast and Market Analysis to 2022
M2 - Thu May 22, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8s2vl4/cebranopadol) has announced the addition of the "Cebranopadol (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering. Cebranopadol (GRT-6005) is a small-molecule opioid analgesic that is being developed by Gr?nenthal for the treatment of moderate to severe chronic pain conditions. In December 2010, Gr?nenthal entered into a licensing agreement with Forest Laboratories for the co-development and commercialization of cebranopadol and its follow-on compound, GRT-6006. The drug is currently in Phase IIb of clinical development for PDN, and is also in Phase III of development for cancer pain, as well as in Phase II for chronic nociceptive pain, moderate to severe pain due to osteoarthritis of the knee, and chronic low back pain. Scope - Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cebranopadol including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cebranopadol for the top six countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain and the UK. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Painful Diabetic Neuropathy - Postherpetic Neuralgia - Trigeminal Neuralgia - Etiology - Pathophysiology 4 Disease Management - Diagnosis - Treatment Overview and Guidelines 5 Competitive Assessment 6 Unmet Need and Opportunity - Physician Knowledge or Awareness - Diagnostic Challenges - Low Treatment Rate and Underdosing of Medications - Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments - Elderly Patient Population - Drug Tolerability - Rational or Personalized Therapies 7 Pipeline Assessment - Promising Drugs in Clinical Development 8 Cebranopadol - Overview - Efficacy - Safety - Dosing and Formulation - Potential Clinical and Commercial Positioning - Pricing and Reimbursement - SWOT Analysis - Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/8s...branopadol
Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition"
of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition"
of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Conference Schedules, Acquisition Updates, Global Footprints, and Technical Updates - Analyst Notes on Forest, CR Bard, Mallinckrodt, Covidien and WellPoint
PR Newswire - Wed May 21, 8:01AM CDT
Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), CR Bard Inc. (NYSE: BCR), Mallinckrodt plc (NYSE: MNK), Covidien plc (NYSE: COV) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2742-100free.
Adamas Pharmaceuticals awarded USD25m milestone payment for FDA acceptance of MDX-8704 NDA for planned moderate-to-severe dementia of the Alzheimer's type in the US
M2 - Wed May 21, 5:49AM CDT
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of a USD25m milestone payment from Forest Laboratories Holdings related to the development of MDX-8704.
Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
PR Newswire - Tue May 20, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has received a $25 million milestone payment from Forest Laboratories Holdings Limited related to the development of MDX-8704. MDX-8704, a fixed-dosed combination (FDC) of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the United States.
Will This Price Target Increase Help Forest Laboratory (FRX) Stock Today?
at The Street - Mon May 19, 8:18AM CDT
UBS raises its price target for Forest Laboratory (FRX) to $94 from $72, reiterating its 'neutral' rating, citing a recent takeover offer.
Global Nutrition and Vitamin Partnering Market: Updated 2014 Report
M2 - Mon May 19, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/246gjd/nutrition_and) has announced the addition of the "Global Nutrition and Vitamin Partnering Market: Updated 2014 Report" report to their offering. Global Nutrition and Vitamin Partnering Market: Updated 2014 Report is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in nutrition & vitamins dealmaking in the biopharma industry since 2009 Access to summary headline, upfront, milestone and royalty data The leading nutrition & vitamins deals by value since 2009 Global Nutrition and Vitamin Partnering Market: Updated 2014 Report, the available deals are listed by: - Headline value - Upfront payment value - Royalty rate value - Company A-Z - Industry sector - Stage of development at signing - Deal component type - Technology type - Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in nutrition & vitamins partnering Chapter 3 - Leading nutrition & vitamins deals Chapter 4 - Dealmaking directory Chapter 5 - Partnering resource center Appendices Companies Mentioned: - Abbott - Actavis - Actelion - Allergan - Amgen - Aspen Pharmacare - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgene - CSL - Daiichi Sankyo - Dainippon Sumitomo - Eisai - Eli Lilly - Endo Pharmaceuticals - Forest Laboratories - Galderma - Gilead Sciences - GlaxoSmithKline - Grifols - Hospira - Johnson & Johnson - Kyowa Hakko Kirin - Lundbeck - Menarini - Merck & Co - Merck KGaA - Mitsubishi Tanabe - Novartis - Novo Nordisk - Otsuka - Pfizer - Purdue - Roche - Sanofi - Servier - Shionogi - Shire - Takeda - Teva - Valeant - Warner Chilcott - Watson For more information visit http://www.researchandmarkets.com/research/24...rition_and
Forest Laboratories, Inc. to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference
Business Wire - Fri May 16, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it will present data on aclidinium, aclidinium/formoterol combination, and roflumilast at the American Thoracic Society (ATS) 2014 International Conference scheduled for May 16-21, 2014, in San Diego. Ten posters and two poster discussion sessions will be presented for aclidinium and aclidinium/formoterol. Roflumilast data will be highlighted in four posters and one mini symposia presentation.
Forest Laboratories, Inc. to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting
Business Wire - Fri May 16, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that data on an investigational fixed-dose combination (FDC) of nebivolol and valsartan will be presented at the American Society of Hypertension (ASH) Annual Scientific Meeting scheduled May 16-20, 2014 in New York. Forest recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for the nebivolol/valsartan FDC for the treatment of hypertension.
SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Furiex Pharmaceuticals, Inc. to Forest Laboratories, Inc. and Royal Empress, Inc. -- FURX
GlobeNewswire - Wed May 14, 6:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the Delaware Chancery Court on behalf of all common stockholders of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company"
(Nasdaq:FURX) asserting claims that the members of the Company's board of directors have breached fiduciary duties they owe to Furiex shareholders. Synergy Pharma Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 10:00AM CDT
Synergy Pharma (SGYP) reported first quarter 2014 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
Business Wire - Tue May 13, 12:39PM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
(NasdaqGS: FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court. INVESTOR ALERT: Levi & Korsinsky, LLP Announces Notifies Investors of Furiex Pharmaceuticals, Inc. of Claims Against Board of Directors of Company In Connection With the Sale of the Company to Forest Laboratories, Inc. -- FURX
Business Wire - Tue May 13, 12:34PM CDT
Levi & Korsinsky notifies investors of Furiex Pharmaceuticals, Inc. ("Furiex" or "the Company"
(NasdaqGS: FURX) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Forest Laboratories, Inc. ("Forest" . A complaint was filed in Delaware state court. Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest
PR Newswire - Tue May 13, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Novartis AG (NYSE: NVS), Cigna Corp. (NYSE: CI) and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2384-100free.
RiverVest Venture Partners' Portfolio Company Lumena is Sold to Shire for $260 million; Represents Sixth Exit from RiverVest Venture Fund II
Business Wire - Mon May 12, 9:39AM CDT
RiverVest Venture Partners today announced portfolio company Lumena Pharmaceuticals has been sold to Dublin-based Shire Plc., in a transaction with an upfront payment of $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.
